Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Amyloidosis × Vinorelbine × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 3 Neoplasms, Plasma Cell 1 Leukemia 1 Amyloidosis 1

Interventions

Dexamethasone 16 Melphalan 9 Calcium Dobesilate 8 Bortezomib 7 Cyclophosphamide 6 Lenalidomide 5 miridesap 3 venetoclax 2 pomalidomide 2 ixazomib 2 belantamab mafodotin 2 Thalidomide 2 Doxycycline 2 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2 dexamethasone acetate 1 dexamethasone 21-phosphate 1 daratumumab 1 carfilzomib 1 birtamimab 1 auricularum 1 Vinorelbine 1 Technetium Tc 99m Pyrophosphate 1 Technetium 1 Tacrolimus 1 Surveys and Questionnaires 1 Pharmaceutical Preparations 1 Lisaftoclax 1 Interleukin-2 1 Hyaluronoglucosaminidase 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02791373 2018-04-03

ViGeM

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡